Neuphoria Therapeutics (NEUP) Share-based Compensation (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Share-based Compensation of $70286.0 for Q1 2026, up 243.43% year-over-year from $20466.0 in Q1 2025, and down 24.99% quarter-over-quarter from $93701.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Share-based Compensation (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Share-based Compensation for 4 consecutive years, with $70286.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 243.43% year-over-year to $70286.0; the TTM figure through Mar 2026 stood at $409759.0 (up 132.97% YoY), while the FY2025 annual figure was $200000.0, down 75.45% from the prior year.
- Share-based Compensation slipped to $70286.0 in Q1 2026 per NEUP's latest filing, from $93701.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $746936.0 in Q4 2023 and bottomed at $20466.0 in Q1 2025.
- Historically, Share-based Compensation has averaged $137551.1 across 4 years, with a median of $93701.0 in 2025.
- Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 97.19% — and 2025, when it jumped 346.83%.
- Neuphoria Therapeutics' Share-based Compensation stood at $746936.0 in 2023, then sank by 97.19% to $20970.0 in 2024, then surged by 346.83% to $93701.0 in 2025, then slipped by 24.99% to $70286.0 in 2026.
- Business Quant data shows NEUP's Share-based Compensation at $70286.0 in Q1 2026, $93701.0 in Q4 2025, and $111277.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70,286.00 |
| Mar 31, 2026 | 70,286.00 |
| Dec 31, 2025 | 93,701.00 |
| Dec 31, 2025 | 93,701.00 |
| Sep 30, 2025 | 111,277.00 |
| Sep 30, 2025 | 111,277.00 |
| Jun 30, 2025 | 134,495.00 |
| Jun 30, 2025 | 134,495.00 |
| Mar 31, 2025 | 20,466.00 |
| Mar 31, 2025 | 20,466.00 |
| Dec 31, 2024 | 20,970.00 |
| Dec 31, 2024 | 20,970.00 |
| Sep 30, 2024 | 26,736.00 |
| Sep 30, 2024 | 26,736.00 |
| Jun 30, 2024 | 107,716.00 |
| Jun 30, 2024 | 107,716.00 |
| Mar 31, 2024 | 40,031.00 |
| Mar 31, 2024 | 40,031.00 |
| Dec 31, 2023 | 746,936.00 |
| Dec 31, 2023 | 746,936.00 |